Author's response to reviews

Title: Intravitreal vs. Subtenon Triamcinolone Acetonide for the treatment of diabetic cystoid macular edema

Authors:

Mauro Cellini (mauro.cellini@unibo.it)
Alberto Pazzaglia (angela.ungarelli@unibo.it)
Eugenio Zamparini (ezampar@tin.it)
Pietro Leonetti (pietro.leonetti@yahoo.it)
Emilio C Campos (emilio.campos@unibo.it)

Version: 4 Date: 19 December 2007

Author's response to reviews: see over
Dear Dr. Cassidy-Cain,

here enclosed you will find a point-by-point replay to the reviewers' comments and the revision version of the manuscript entitled: **Intravitreal vs. Subtenon Triamcinolone Acetonide for the treatment of diabetic cystoid macular edema.**

Osman Cekic

1. I corrected the number of patients in the abstract that are 14 (see methods)
2. All patients previously was treated with focal laser in the macula
3. The data were statistically evaluated using the Wilcoxon signed rank test and a p<0.05 was considered significant. Data are presented as means±standard deviation (SD). The analysis was performed using SSI (version 11, Systat Software Inc., San Jose, California, USA) for Macintosh.
4. We don't observe any cataract evolution in our patients and we don't use glaucoma medication after intravitreal or subtenon injection of triamcinolone.
5. The subtenon injection of 40 mg. of triamcinolone is needed to achieve an intravitreal amount of triamcinolone like this of the intravitreal injection that I

Makoto Inoue

1. I have mentioned the volume of triamcinolone in the abstract
2. I corrected the number of patients in the abstract that are 14 (see methods)
3. All patients previously was treated with focal laser in the macula
4. The data were statistically evaluated using the Wilcoxon signed rank test and a p<0.05 was considered significant. Data are presented as means±standard deviation (SD). The analysis was performed using SSI (version 11, Systat Software Inc., San Jose, California, USA) for Macintosh
5. I have clarified that all patients are phakic
6. I have modified the decimal point of IOP and macular thickness data
7. In the scientific literature (Pub Med) I have found only a report about the use of systemic acetazolamide in diabetic macular edema (Giusti C, Forte R, Vingolo EM, Gargiulo P.- Is acetazolamide effective in the treatment of diabetic macular edema? A pilot study. Int Ophthalmol 2001;24(2):79-88). The authors found only a decrease of the leakage in the macular region after three months. I think that the use of 250 mg twice daily for two days before intravitreal injection is ineffective on the macular thickness.
8. I have corrected the other minor points

I hope that the revision version it is O.K. for a positive judgement of the referees.

Sincerely yours

Dr. Mauro Cellini